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Abstract
The C-type lectin receptor DCIR, which has been shown very recently to act as an attachment factor for HIV-1 in dendritic cells,
is expressed predominantly on antigen-presenting cells. However, this concept was recently challenged by the discovery that
DCIR can also be detected in CD4
+ T cells found in the synovial tissue from rheumatoid arthritis (RA) patients. Given that RA
and HIV-1infectionssharecommonfeaturessuchasachronicinflammatoryconditionandpolyclonalimmunehyperactivation
status, we hypothesized that HIV-1 could promote DCIR expression in CD4
+ T cells. We report here that HIV-1 drives DCIR
expression in human primary CD4
+ T cells isolated from patients (from both aviremic/treated and viremic/treatment naive
persons) and cells acutely infected in vitro (seen in both virus-infected and uninfected cells). Soluble factors produced by virus-
infected cells are responsible for the noticed DCIR up-regulation on uninfected cells. Infection studies with Vpr- or Nef-deleted
viruses revealed that these two viral genes are not contributing to the mechanism of DCIR induction that is seen following
acute infection of CD4
+ T cells with HIV-1. Moreover, we report that DCIR is linked to caspase-dependent (induced by a
mitochondria-mediated generation of free radicals) and -independent intrinsic apoptotic pathways (involving the death
effector AIF). Finally, we demonstrate that the higher surface expression of DCIR in CD4
+ T cells is accompanied by an
enhancement of virus attachment/entry, replication and transfer. This study shows for the first time that HIV-1 induces DCIR
membrane expression in CD4
+ T cells, a process that might promote virus dissemination throughout the infected organism.
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Introduction
The Dendritic Cell ImmunoReceptor (DCIR) is a recently
described member of the C-type lectin family. It is mainly expressed
in cells of the myeloid lineage (i.e. neutrophils, dendritic cells,
monocytes and macrophages) and also in B cells [1]. Its precise role
and function are not completely understood but a recent work has
suggested that DCIR might regulate expansion of dendritic cells
(DCs) [2]. Moreover, it was previously established that DCIR can
behave as an attachment factor for human immunodeficiency virus
type-1 (HIV-1) on DCs and contribute possibly to virus dissemina-
tion by promoting both cis-a n dtrans-infection processes [3].
Interestingly, DCIR is expressed on the surface of CD4
+ T cells in
rheumatoid arthritis (RA) patients before glucocorticoid treatment
and a decrease of DCIR expression was seen with disease
improvement [4]. This study provides the first indication that
DCIR expression in CD4
+ T cells can be promoted by
inflammatory and immune hyperactivated conditions since RA is
considered as a chronic, systemic inflammatory disorder character-
ized by a chronic T-cell response that has escaped normal control
mechanisms [4,5]. In addition, an increased surface expression of
DCIR has been detected in patients suffering from a myocardial
infarction [4], which corroborates that this molecule is induced by
an inflammatory environment.
It is now well established that HIV-1 infection causes a slow but
progressive impairment of the immune system, which is accom-
panied by a chronic hyperactivation of CD4
+ and CD8
+ T cells
[6,7,8]. Consequently, infected patients display a heightened
expression of various activation markers such as HLA-DR and
CD38 in both CD4- and CD8-expressing T cells [9]. A relentless
destruction of CD4
+ T cells represents another hallmark of HIV-1
infection. The progressive loss of CD4
+ T lymphocytes, either
infected or uninfected (also called bystander), occurs through
several distinct mechanisms. For example, it has been proposed
that cell death is resulting from direct killing of virus-infected cells
[10], elimination of HIV-1-infected CD4
+ T cells by cytotoxic T
lymphocytes (CTL) [11], syncytia formation through a gp120-
mediated cell-to-cell fusion process [10], cytotoxic effects caused
by some soluble viral proteins (e.g. Tat and Vpr) [10] and, finally,
increased susceptibility to apoptosis in both infected and bystander
cells that can be due, for example, to an interaction between the
external envelope protein of HIV-1 (i.e. gp120) and primary
cellular receptor/coreceptor (i.e. CD4 and CXCR4 or CCR5)
[10,12]. Importantly, previous studies suggest a direct correlation
between the magnitude of apoptosis in circulating CD4
+ T cells
and disease pathogenesis [13,14].
During evolution, the immune system has developed a number
of strategies to fight viral infections, such as necrosis, autophagy
and apoptosis. The last physiological mechanism is used by the
body to eliminate overabundant cell populations and defective
cells, and this form of cell death displays a propensity to be
amplified and/or deregulated in various pathological processes
[15]. Two major signalling pathways have been described to be
involved in apoptosis induction, i.e. the intrinsic and extrinsic
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disruption of the mitochondrial membrane and the release of
mitochondrial proteins, such as cytochrome c, into the cytoplasm
after developmental cues or severe cell stresses, such as DNA
damage [16]. The extrinsic pathway is activated by the binding of
ligands such as Fas ligand (FasL) (also termed CD95L), tumor
necrosis factor (TNF), and TRAIL/Apo-2 ligand to their death
receptors Fas/CD95/Apo-1, TNFR1 and DR4/DR5, respectively.
These two pathwaysconvergevia activationofintracellularcaspase-
3 and -7. The caspase biochemical cascade ultimately triggers cell
death through the destruction of cellular proteins and induction of
DNA fragmentation [16]. It is known that apoptosis can also result
from a caspase-independent process, which relies on the apoptosis-
inducing factor (AIF). AIF represents the first mitochondrial protein
shown to mediate cell death without the requirement for caspases.
This protein is released from mitochondria and translocates to the
nucleus, where it mediates nuclear features of apoptosis such as
chromatin condensation and DNA degradation [17].
It has been shown that HIV-1 induces apoptosis in both infected
and bystander immune effector cells [18,19]. It has been
established that at least five different virus-encoded proteins can
induce apoptosis (i.e. Env, Tat, Nef, protease and Vpr) and three
of them share a capacity to induce cell surface expression of death
ligands and receptors of the TNF family (i.e. Env, Tat and Nef).
Previous work indicates that HIV-1 induces a mitochondrial
membrane permeabilization and release of AIF [20]. The
regulatory protein Nef can confer protection against apoptosis
but display also a converse capacity to induce apoptosis in
neighbouring immune effector cells [21]. Cross-linking of CD4
molecules is the probable mechanism by which the virus-encoded
gp120 can cause apoptosis in bystander CD4
+ T cells [12,22].
Moreover, the viral protease, which inactivates anti-apoptotic Bcl-
2 with a concomitant induction of the pro-apoptotic procaspase-8,
renders the cell more prone to mitochondrial dysfunctions in
response to internal or external death signals [23]. It has been
proposed that apoptosis of bystander cells in the context of HIV-1
infection is likely to be multifactorial. Possible mechanisms include
soluble factors secreted by HIV-1-infected cells as well as virus-
encoded proteins (e.g. Env, Nef, TAT and Vpr) [24,25]. For
example, supernatants from HIV-1-infected DCs contain several
heat labile soluble factors that mediate the killing of bystander
thymocytes [26] and soluble factors were found to induce
apoptosis in bystander cells [27,28]. In addition, the viral accessory
protein Vpr mediates apoptosis of bystander cells by causing the
release of AIF [24].
Therefore given that RA and HIV-1 infection are both
characterized by inflammatory and immune hyperactivation
conditions and considering the recently described link between
RA and DCIR expression in CD4+ T cells, we hypothesized that
HIV-1 can trigger DCIR expression in CD4+ T cells.
Results
DCIR is up-regulated in CD4
+ T cells from HIV-1-infected
persons and following acute infection in vitro
DCIR has been detected in CD4
+ T cells originating from
patients with active RA, a chronic disease characterized by a state
of persistent inflammation and immune activation. Because a
systemic inflammatory disorder and immune hyperactivation
represent also key features of the HIV-1 infection, we first assessed
DCIR expression in CD4
+ T cells isolated from infected
individuals. To this end, the level of ex vivo DCIR expression
was evaluated by flow cytometry in peripheral blood CD4
+ T cells
from two HIV-1-infected aviremic/treated patients. Results
depicted in Figure 1A clearly indicate that DCIR is expressed in
this cell subset in the context of a natural infection as opposed to
what is seen in cells from uninfected healthy donors. Flow
cytometry analyses were also performed on circulating CD4
+ T
cells from additional seropositive individuals but who were this
time viremic and treatment-naive. Again an up-regulation of
DCIR expression was detected in such samples (Figure 1B), which
supports the concept that HIV-1 infection promotes expression of
this C-type lectin receptor on the surface of circulating CD4
+ T
cells. A cell activation marker was also monitored as well (i.e.
HLA-DR) and a positive correlation was found between DCIR
and HLA-DR since both cell surface constituents were found to be
increased in CD4
+ T cells from viremic/treatment-naive persons
compared to uninfected control samples (data not shown).
In an attempt to investigate further the capacity of HIV-1 to
promote DCIR expression, in vitro studies were performed using
human primary CD4
+ T cells acutely infected with X4- and R5-
using virus isolates (i.e. NL4-3 and NL4-3/Balenv, respectively).
Exposure of purified CD4
+ T cells to NL4-3 for 3 days triggers
DCIR expression on the cell surface (Figure 1C). Similar observa-
tions were made when infection was carried out in parallel with the
two tested viral isolates. For example, DCIR was detected in
9.061.5% and 8.660.8% of CD4
+ T cells inoculated with NL4-3
and NL4-3/Balenv, respectively (n=3) (data not shown). In some
experiments, cells were first pre-treated with the antiretroviral drug
efavirenz (EFV) before virus infection. This experimental strategy
was used to decipher if the virus-mediated induction of DCIR
requires a complete replicative cycle (i.e. productive infection).
Treatment of purified CD4
+ T cells with EFV reduced significantly
the percentage of DCIR-expressing cells, thus indicating that
productive infection with HIV-1 is mandatory to lead to DCIR
expression.Altogether theseresults suggest that HIV-1drives DCIR
expression in vivo and in vitro in CD4
+ T cells, a cell population
recognized as a major cellular reservoir for HIV-1.
Experiments were also performed with Vpr- or Nef-deleted
mutant to define the possible contribution of each single gene in
the virus-mediated induction of DCIR expression on the surface of
CD4
+ T cells. Induction of DCIR was similar when cells were
acutely infected with wild-type and Vpr- or Nef-deleted mutant
viruses (data not shown).
HIV-1 induces DCIR expression in both infected and
bystander CD4
+ T cells
We next set out to determine whether induction of DCIR
occurs in virus-infected and/or bystander cells. This fundamental
Author Summary
The type II transmembrane protein DCIR belongs to the C-
type lectin domain family receptor and is predominantly
expressed in cells of the myeloid lineage. However recent
evidence suggests that it can also be induced in CD4
+ T
cells placed under an inflammatory condition. We assessed
the capacity of HIV-1 to promote DCIR expression in CD4
+
T cells because the establishment of an inflammatory state
is a hallmark of this retroviral infection in humans. We
report here that a higher DCIR expression is detected not
only in CD4
+ T cells acutely infected with HIV-1 in vitro but
also in clinical cell samples. Additional studies suggest a
possible link between DCIR induction and apoptosis
through both caspase-dependent and -independent in-
trinsic pathways. The greater expression of DCIR on the
surface of CD4
+ T cells results in more efficient virus
attachment/entry, replication and transfer processes.
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PLoS Pathogens | www.plospathogens.org 2 November 2010 | Volume 6 | Issue 11 | e1001188Figure 1. HIV-1 induces DCIR expression in CD4+ T cells under both in vivo and in vitro conditions. Purified CD4
+ T cells were isolated
from uninfected healthy donors and two HIV-1-infected aviremic/treated persons (P,0.05) (A) or three viremic/treatment-naive patients (P,0.001)
(B). Next, cells (1610
6) were stained with the R-PE-labeled anti-DCIR monoclonal Ab. Expression of DCIR is shown as a dotted line, whereas the
continuous line represents staining obtained with an isotype-matched irrelevant control Ab. For uninfected healthy donors, data shown correspond
to a single experiment representative of 5 distinct donors. (C) Purified human primary CD4
+ T cells (1610
6) were pulsed or not with NL4-3 (100 ng of
p24). Three days later, DCIR expression was evaluated by flow cytometric analysis through the use of a R-PE-labeled anti-DCIR monoclonal Ab.
Expression of DCIR is shown as a dotted line, whereas the continuous line represents results obtained with an isotype-matched irrelevant control Ab.
Data shown in panel C correspond to a single experiment representative of 3 independent experiments (P,0.01). Statistical analyses were made by
comparing fluorescence intensities in samples from HIV-1-infected patients or NL4-3-infected cells and the isotype-matched irrelevant control Ab.
doi:10.1371/journal.ppat.1001188.g001
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construct, NL4-3-IRES-HSA, which, unlike most of the previous
reporter constructs, will lead to the production of fully competent
virions [29]. This X4-tropic infectious molecular clone of HIV-1
codes for all viral genes, with no deletions in env, vpr,o rnef. It also
expresses a cell surface reporter molecule, the murine heat-stable
antigen (HSA), which permits the detection by flow cytometry of
cells productively infected with HIV-1 through the surface
expression of the HSA molecule. Briefly, human primary CD4
+
T cells were exposed to NL4-3-IRES-HSA for 3 days and surface
expression of HSA and DCIR was monitored by flow cytometry.
Data shown in Table 1 demonstrate that 15.863.1% of cells are
productively infected with HIV-1 (i.e. HSA-positive), whereas
DCIR is expressed in 5.060.8% of cells and 2.360.2% of cells
express both HSA and DCIR (n=3) (a representative donor is
depicted in Figure 2). Therefore, about 46% of DCIR-expressing
cells are infected with HIV-1 and 56% of DCIR-positive cells are
uninfected. It can be concluded that HIV-1 infection of CD4
+ T
cells promotes membrane expression of this C-type lectin surface
receptor in both virus-infected and bystander cells.
DCIR expression in bystander cells is due to soluble
factors produced by CD4
+ T cells productively infected
with HIV-1
Our previous findings indicate that HIV-1 induces DCIR
expression not only in virus-infected but also in bystander cells as
well. Our next set of experiments was aimed at defining the
possible involvement of soluble factors produced by infected cells
in the up-regulation of DCIR seen in bystander cells. To this end,
human primary CD4
+ T cells were cultured with cell-free culture
supernatants from HIV-1-infected cells and DCIR expression was
monitored by flow cytometry. As shown in Figure 3, exposure of
CD4
+ T cells to supernatants originating from cells acutely
infected with HIV-1 is sufficient per se to drive DCIR expression in
the three distinct donors studied.
Correlation between HIV-1-mediated DCIR expression
and apoptosis through both caspase-dependent and
-independent intrinsic pathways
The HIV-1-mediated induction of apoptosis in both infected
and bystander CD4
+ T cells is a well-described phenomenon
[30,31,32]. The peak of apoptosis is observed usually after 2 to 3
days [20], the same time frame in which we detected the HIV-1-
dependent induction of DCIR. Therefore, we next assessed
whether there might be a connection between the virus-induced
DCIR expression and apoptosis. We initially assessed the ability of
NL4-3-IRES-HSA reporter virus to drive apoptosis in CD4
+ T
cells using FITC-VAD-FMK staining. This fluorochrome-labeled
pan-caspase inhibitor is a specific and convenient-to-use marker of
apoptotic cells, which can identify very early events of apoptosis
associated with caspase activation (i.e. pre-apoptotic cells) [33].
Our studies indicate that NL4-3-IRES-HSA virions can potently
mediate apoptosis in human primary CD4
+ T cells (data not
shown). As expected, the percentages of apoptotic cells in both
virus-infected (i.e. HSA-positive) and bystander cells (HSA-
negative) were significantly reduced upon EFV treatment (data
not shown). To establish a link between DCIR expression and
apoptosis following HIV-1 infection, we carried out a series of
investigations with the broad-spectrum caspase inhibitor Z-VAD-
FMK [34]. As illustrated in Figure 4, the HIV-1-mediated DCIR
up-regulation was partially reduced in presence of Z-VAD-FMK,
thus suggesting that the virus-directed increased expression of
DCIR is associated with both caspase-dependent and -indepen-
dent apoptotic pathways.
To shed light on the nature of the caspase-independent death
mechanism, we studied the involvement of the apoptotic effector
protein AIF based on the previous report showing that HIV-1
Figure 2. DCIR is expressed in both virus-infected and bystander CD4
+ T cells. Cells (1610
6) were either left (A) uninfected or (B) infected
with NL4-3-IRES-HSA reporter virus (100 ng of p24). Three days later, a double-stain flow cytometric method was performed to assess the
percentages of DCIR-expressing and HSA-positive cells. Data shown correspond to a single experiment representative of 3 independent experiments.
doi:10.1371/journal.ppat.1001188.g002
Table 1. HIV-1 induces DCIR expression in CD4
+ T cells
a.
Cell surface marker Mock NL4-3-IRES-HSA
DCIR 1.060.2
b 5.060.8
HSA 1.260.8 15.863.1
DCIR/HSA 0.660.5 2.360.2
aCD4+ T cells (1610
6) were either left uninfected (mock) or infected with NL4-3-
IRES-HSA (100 ng of p24). Three days later, a double-staining method was used
to estimate DCIR and HSA expression by flow cytometry.
bData shown correspond to the means6SD of triplicate samples from 3 distinct
donors.
doi:10.1371/journal.ppat.1001188.t001
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tosis controlled by AIF [35]. The possible contribution of AIF was
investigated through the use of the inhibitor of apoptosis N-acetyl-
L-cystein (NAC), which blocks nuclear translocation of AIF. Our
results demonstrate that the HIV-1-induced expression of DCIR
on the surface of human primary CD4
+ T cells is inhibited but not
completely by a NAC treatment (i.e. 16.263.4% in HIV-1-
infected cells compared to 6.761.7% in virus-infected cells also
treated with NAC) (n=3) (these three donors are depicted in
Figure 5). Experiments were performed also with both Z-VAD-
FMK and NAC to see if this double treatment can totally inhibit
the virus-mediated induction of DCIR expression. Unfortunately
the concomitant use of the two compounds is leading to cell
toxicity (data not shown). It should be noted that no toxicity is seen
when each compound are tested individually (data not shown).
Nevertheless, we provide evidence that there is a close connection
Figure 3. Soluble factors secreted by virus-infected cells promote DCIR expression. Cell-free supernatants from mock- and HIV-1-infected
cells were used to treat purified CD4
+ T cells. DCIR expression was monitored 3 days later by flow cytometry. Expression of DCIR is shown as a dotted
line, whereas the continuous line represents staining obtained with an isotype-matched irrelevant control Ab. Data shown correspond to studies
performed with three distinct donors.
doi:10.1371/journal.ppat.1001188.g003
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dependent and -independent pathways) after acute infection of
CD4
+ T cells with HIV-1.
HIV-1 infection of CD4
+ T cells results in DCIR expression
partly due to a free radical, caspase-dependent apoptosis
pathway
In HIV-1-infected patients, the hyperactivation status is
accompanied by an increased production of free radicals (e.g.
superoxide anion, hydroxyl radical and hydrogen peroxide). This
excess of reactive oxygen species (ROS) damages cell membranes
and generates apoptosis [36]. To establish a putative relationship
between DCIR expression and apoptosis induced by free radicals
after HIV-1 infection, we performed a double staining with anti-
DCIR and FITC-VAD-FMK in virus-infected CD4
+ T cells
treated with catalase because this enzyme is a known scavenger of
ROS (including hydrogen peroxide). Results depicted in Figure 6
suggest that free radicals are indeed playing a functional role in the
HIV-1-mediated induction of DCIR seen in apoptotic cells (i.e.
positive for both DCIR and FITC-VAD-FMK).
Hydrogen peroxide (H2O2), a representative ROS, has been
extensively used to study apoptosis following an oxidative stress
[37]. Thus, additional experiments were performed in human
primary CD4
+ T cells using H2O2 as an inducer of an apoptotic-
like cell death. Exposure of mitogen-stimulated CD4
+ T cells to
concentrations of H2O2 ranging from 20 to 60 mM led to a dose-
dependent increased in DCIR expression (Figure 7A). Cell
viability was reduced when using doses of H2O2 $45 mM (data
not shown). Consequently, the subsequent experiments were
performed using H2O2 at a final concentration of 30 mM. A
time-course analysis indicated that the H2O2-mediated expression
of DCIR is maximal at 16 h post-treatment and reached a plateau
at a longer time period (i.e. 32 h) (Figure 7B and data not shown).
The specificity of the relation between DCIR expression and
apoptosis was addressed by estimating surface expression of two
other HIV-1 receptors, namely DC-SIGN (used as a negative
control) and CD4. Our data demonstrate that both cell surface
molecules are not modulated upon induction of apoptosis by
H2O2 (data not shown). Importantly, DCIR was promoted as well
by staurosporine (data not shown), a well-known inducer of
apoptosis in a wide range of cell lines [38], which further confirms
the connection between DCIR and apoptosis.
Given that H2O2 induces also necrosis and mediates apoptosis
primarily via a caspase-dependent pathway [39,40], we performed
experiments with Z-VAD-FMK. A pre-treatment with Z-VAD-
FMK prevented DCIR expression in activated CD4
+ T cells after
H2O2 stimulation (i.e. 21.463.4% in H2O2-treated cells compared
to 1.060.2% in cells treated with both H2O2 and Z-VAD-FMK)
(n=3) (a representative donor is depicted in Figure 8A).
Experiments were repeated in quiescent CD4
+ T cells and we
made similar observations (data not shown). Overall our results
indicate that the H2O2-driven induction of DCIR is not due to
necrosis and occurs through a caspase-mediated signal transduc-
tion pathway. Moreover, we estimated the percentages of
apoptotic cells that express DCIR following H2O2 treatment.
Figure 4. Virus-mediated induction of DCIR is partly prevented by a caspase inhibitor. Mitogen-activated CD4
+ T cells (1610
6) were first
either left untreated or treated for 1 h with the caspase inhibitor Z-VAD-FMK (50 nM), after which HIV-1 was added (100 ng of p24), where indicated.
DCIR expression was monitored 3 days later by flow cytometry. Data shown represent the means 6 SD of triplicate samples from three independent
experiments. Asterisks denote statistically significant data (*, P,0.05; **, P,0.01).
doi:10.1371/journal.ppat.1001188.g004
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+ T cells were labelled with
FITC-VAD-FMK and anti-DCIR. We found that 12.263.2% of
apoptotic cells are also positive for DCIR (n=3) (a representative
donor is depicted in Figure 8B), which confirms the relationship
between DCIR and apoptosis in CD4
+ T cells.
HIV-1 binding/entry, infection and transfer processes are
all promoted by ROS-mediated induction of DCIR
Taken together, our findings demonstrated that the HIV-1-
mediated apoptosis promotes DCIR surface expression in CD4
+ T
cells. Previous results indicate that DCIR can capture HIV-1 on
DCs, enhance de novo virus production by DCs (i.e. infection in cis),
and increase DC-mediated virus transmission to CD4
+ T cells (i.e.
infection in trans) [3]. Experiments were thus carried out to define
first whether HIV-1 attachment/entry in CD4
+ T cells can be
affected by the H2O2-dependent increase in DCIR expression. As
illustrated in Figure 9A, the early steps in the virus life cycle (i.e.
binding and entry) are enhanced in CD4
+ T cells following
exposure to H2O2 (i.e. 12.561.8 versus 3.860.8 ng/ml of p24).
We next set out to determine whether acute HIV-1 infection was
also affected under these conditions. A statistically significant
increase in virus production was seen in cells treated with H2O2
(Figure 9B). Similarly, virus transfer was also enhanced when
DCIR-expressing CD4
+ T cells are used as transmitter cells
(Figure 9C). To further strengthen the contribution of DCIR in
the virus trans-infection pathway, CD4
+ T cells were first exposed
to H2O2 to induce DCIR expression. Thereafter, DCIR-negative
and DCIR-positive cells were isolated and used separately in HIV-
1 transfer experiments. Data shown in Figure 9D demonstrate that
HIV-1 transmission toward uninfected CD4
+ T cells (i.e. recipient
cells) is augmented when using, as transmitter cells, DCIR-positive
CD4
+ T cells. Finally, to substantiate the participation of DCIR in
HIV-1 replication, H2O2-treated/virus-infected CD4
+ T cells
were subjected to a dual staining immunofluorescence method to
detect both intracellular HIV-1 p24 and surface DCIR. An
increase in virus binding/entry was detected in H2O2-treated cells
Figure 5. HIV-1-dependent DCIR induction is due also to a caspase-independent process involving AIF. Cells (1610
6) were first either
left untreated or treated for 1 h with NAC, after which HIV-1 (100 ng of p24) was added. DCIR expression was monitored 3 days later by flow
cytometry. Expression of DCIR is shown as a dotted line, whereas the continuous line represents staining obtained with an isotype-matched irrelevant
control Ab. Data shown correspond to 3 independent experiments performed with distinct healthy donors.
doi:10.1371/journal.ppat.1001188.g005
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expressing both DCIR and p24 was detected following acute virus
infection (Figure 9F).
Discussion
It has been already recognized that neutrophils, monocytes,
DCs, macrophages and B cells constitutively express a high level of
DCIR, as opposed to CD4
+ T cells that are negative for DCIR [1].
However, data from a recent work suggest that this type II
membrane glycoprotein is expressed on CD4
+ T cells in RA
patients and the level of DCIR surface expression is higher in the
rheumatic joint compared to peripheral blood [4]. Since DCIR
expression is reduced following a local corticosteroid treatment, it
was proposed that there is a potential connection between an
inflammatory state and DCIR expression [4]. We established
previously that DCIR can serve as an attachment factor for HIV-1
[3], which is the causative agent of AIDS, another disease
characterized by a chronic inflammatory state. Starting from these
initial intriguing observations, we monitored DCIR expression on
Figure 6. H2O2 produced by HIV-1-infected cells promotes DCIR expression. Mitogen-stimulated CD4
+ T cells (1610
6) were either left
untreated or treated with catalase before HIV-1 infection. Three days after virus infection, DCIR expression was measured by flow cytometry. Data
shown represent the means 6 SD of triplicate samples from three independent experiments. Asterisks denote statistically significant data (**, P,0.01;
***, P,0.001).
doi:10.1371/journal.ppat.1001188.g006
Figure 7. H2O2 mediates both apoptosis and DCIR expression. Mitogen-stimulated CD4
+ T cells (1610
6) were exposed to increasing
concentrations of H2O2 for 16 h (A) or treated with a constant dose of H2O2 (i.e. 30 mM) for the indicated time lengths (B). Next, DCIR expression was
assessed by flow cytometry. Data shown represent the ratio of DCIR expression over basal expression. The ratio is calculated from the means 6 SD of
triplicate samples from three independent experiments. Asterisks denote statistically significant data (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.ppat.1001188.g007
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+ T cells isolated from HIV-1-
carrying patients. We report here that DCIR is expressed on
CD4
+ T cells originating from aviremic/treated and viremic/
untreated seropositive patients, whereas, no expression was
detected in cells from healthy donors. These results suggest that
DCIR expression on the surface of circulating CD4
+ T cells seems
to be a generalized phenomenon in the context of various
inflammatory diseases.
To acquire additional information about the ability of HIV-1 to
induce DCIR expression in a cell subpopulation that is infected
under physiological conditions, we performed in vitro experiments
where human primary CD4
+ T cells were acutely infected with
X4- and R5-tropic virions and monitored DCIR expression. We
showed that HIV-1 drives DCIR expression in both infected and
bystander cells. Moreover, we monitored DCIR levels in the CD4
+
T cell subpopulation following acute HIV-1 infection of
unseparated peripheral blood mononuclear cells. Unfortunately,
no conclusive data could be obtained because we detected a high
mortality rate probably due to the presence of CD8
+ T cells. In
HIV-1 infection, disease progression correlates with elevated levels
of apoptosis [13]. Therefore, we defined whether expression of the
immunoreceptor DCIR on the surface of CD4
+ T cells in the
context of HIV-1 infection could perhaps be considered as a
possible marker of apoptosis for these cells. We performed
experiments and discovered effectively that there is a certain
correlation between HIV-1 infection, DCIR expression and
induction of apoptosis. We provide evidence that there is a
connection between HIV-1-mediated induction of DCIR expres-
sion and apoptosis, the latter being caused by a caspase-dependent
pathway in response possibly to a mitochondrial H2O2 generation
by virus-infected cells and a caspase-independent process involving
AIF. Our data are in agreement with published reports since Vpr
has been shown to induce cell death via the mitochondrial caspase-
independent death effector AIF [35] and Vpr can also induce a
decrease of mitochondrial membrane potential along with the
release of cytochrome c [41].
HIV-1 infection induces prolonged immune system activation
that may cause local or systemic oxidative stress and thus result in
oxidative damage. Oxidative stress occurs when the balance of
antioxidant protection and the production of free radicals,
Figure 8. H2O2 treatment drives DCIR expression in both nonapoptotic and apoptotic cells. (A) Mitogen-activated CD4
+ T cells (1610
6)
were first either left untreated or treated for 1 h with the caspase inhibitor Z-VAD-FMK (50 nM), after which H2O2 (30 mM) was added, where
indicated. DCIR expression was monitored 16 h later by flow cytometry. Expression of DCIR is shown as a dotted line, whereas the continuous line
represents staining obtained with an isotype-matched irrelevant control Ab. Data shown correspond to a single experiment representative of 3
independent experiments. (B) Mitogen-stimulated CD4
+ T cells (1610
6) were first treated for 16 h with H2O2 (i.e. 30 mM). Thereafter, DCIR surface
expression and caspase activation were monitored by flow cytometric analysis using a double-staining method consisting of FITC-VAD-FMK followed
by the R-PE-conjugated anti-DCIR. Data shown correspond to a single experiment representative of 4 independent experiments.
doi:10.1371/journal.ppat.1001188.g008
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PLoS Pathogens | www.plospathogens.org 9 November 2010 | Volume 6 | Issue 11 | e1001188Figure 9. HIV-1 attachment/entry, replication and transfer processes are all promoted in H2O2-treated CD4
+ T cells. Target CD4
+ T
cells (1610
6) were treated for 16 h with H2O2 (30 mM) to induce surface expression of DCIR. (A) Cells were next exposed to NL4-3 (100 ng of p24) for
1 h at 37uC, extensively washed to remove unabsorbed virons before assessing the p24 content. (B) Cells were first incubated with NL4-3 (100 ng of
p24) for 2 h at 37uC, washed extensively to remove input virus and cultured in complete culture RPMI-1640 medium supplemented with rhIL-2 for the
indicated number of days. Cell-free supernatants were collected and assayed for the p24 content. (C) Cells were exposed to NL4-3 (100 ng of p24) for
2 h at 37uC, next washed extensively to remove input virus, and finally co-cultured with autologous CD4
+ T cells in complete culture RPMI-1640
medium supplemented with rhIL-2 for the indicated number of days. Cell-free supernatants were collected and assayed for the p24 content. Virus
production at day 2 is depicted in the small inserts (panels B and C). (D) Cells were exposed to NL4-3 (100 ng of p24) for 2 h at 37uC, washed
extensively to remove input virus, and maintained in complete culture medium supplemented with rhIL-2 for 3 days. Next, DCIR-negative and -
positive cells (used as transmitter cells) were isolated with magnetic beads and co-cultured with uninfected CD4
+ T cells (used as recipient cells). Cell-
free supernatants were collected at 3 days following initiation of the co-culture and assayed for the p24 content. (E) Cells were first exposed to NL4-3
for 2 h at 37uC. Cells were extensively washed to remove unabsorbed virions and half of the cells were used to estimate the percentage of cells
positive for surface DCIR and intracellular p24. (F) The other half was maintained for 3 days in culture before assessing both DCIR and p24. Data
shown represent the means6SD of triplicate samples and correspond to a single experiment representative of three independent experiments.
Asterisks denote statistically significant data (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.ppat.1001188.g009
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[42,43]. Some viral proteins play a role in the intracellular increase
of ROS (e.g. superoxide anion, hydroxyl radical and hydrogen
peroxide) which in turn influence the increase in the apoptotic
index causing a decrease of CD4
+ T cells and more importantly
increase in HIV-1 replication secondary to free radicals overpro-
duction [42]. This excess of ROS damages cell membranes and
generates apoptosis [36]. This may account for the loss of CD4
+ T
cells seen during progression of HIV-1 infection toward AIDS.
Oxygen radicals produced under circumstances that occur during
opportunistic infections mediate apoptosis and this effect is
reversed by oxygen radical scavengers [44]. We corroborated that
human primary CD4
+ T cells are sensitive to apoptosis caused by
H2O2, a representative ROS that has been extensively used to
study apoptosis following an oxidative stress [37]. Based on this
information and the previous demonstration that free radicals are
actively produced by CD4
+ T cells from HIV-1-carrying patients
[36], we showed here that H2O2 induces also DCIR expression.
The H2O2-mediated induction of apoptosis was not only detected
in human primary CD4
+ T cells but also in Raji and 293T cells
(data not shown). No increase in DCIR expression was seen when
using a previously reported anti-Fas monoclonal antibody [45]
(data not shown), which is an effector of the extrinsic apoptosis
pathway [46]. These results indicate that the DCIR induction in
CD4
+ T cells seen after HIV-1 infection is partly associated with a
caspase-dependent intrinsic apoptotic process.
An increased expression of DCIR was also observed in a
proportion of bystander cells undergoing apoptosis. Experiments
carried out with cell-free supernatants from HIV-1-infected cells
revealed that soluble factors are sufficient to drive not only apoptosis
but also DCIR expression. The phenomenon of bystander cell
apoptosis is well described in the literature. Indeed, numerous viral
proteins have been described as responsible for causing apoptosis in
bystander cells (e.g. Env, Nef, TAT and Vpr) [24]. Supernatants
from HIV-1-infected DCs contain several heat labile soluble factors
thatcausecelldeathinbystanderthymocytes[26]andsolublefactors
were shown to induce apoptosis in bystander cells [27,28]. The
transactivating protein Tat is released in the surrounding microen-
vironment and can be taken up by neighbouring bystander cells,
which will ultimately undergo apoptosis [28,47]. Vpr has been
detected in sera and cerebrospinal fluid from HIV-1-infected
patients [48,49] and this protein of viral origin is recognized as a
potentinducerofcelldeathviaacaspase-independentmitochondrial
pathway [24,35]. Recently, Lenassi and co-workers established that
Nef induces the release of exosomes from T cells, which transport
extracellular Nef and cause apoptosis of bystander CD4
+ Tc e l l s
[50]. Surprisingly, studies with Nef- or Vpr-deleted mutants suggest
that these two viral genes are not involved in the HIV-1-mediated
induction of DCIR expression in CD4
+ T cells. Therefore, it can be
proposed that the virus-directed induction of DCIR and apoptosis is
caused by a multifactorial phenomenon that needs to be identified.
More relevant to the pathogenesis of HIV-1 infection, we
demonstrated that the H2O2-mediated induction of DCIR and
apoptosis is coupled with an increased virus binding/entry and
higher replication of HIV-1 in CD4
+ T cells. Additionally, the
noticed up-regulated DCIR expression is also leading to more
efficient virus propagation. It can be proposed that DCIR, once
expressed onto such CD4
+ T cells, can participate actively to HIV-
1 propagation. Although it might seem irrational that apoptotic
cells would be more susceptible to productive HIV-1 infection, it
should be stated that the fluorochrome-labeled pan-caspase
inhibitor FITC-VAD-FMK, which was used to monitor the link
between HIV-1-mediated DCIR expression and apoptosis,
permits to identify the very early events of apoptosis (i.e. pre-
apoptotic cells). Thus it is possible that virus binding/entry and
replication processes can still occur during a certain time period in
CD4
+ T cells that are in a pre-apoptotic state. It is known that
HIV-1 exploits different strategies to escape the immune response
including a rapid/high mutation rate, down-regulation of major
histocompatibility complex class-I molecules, broad coreceptor
usage and destruction of both CD4- and CD8-expressing T cells
[51]. We suggest that HIV-1 can utilize DCIR as another tactic for
escaping the immune system and/or increasing its infectivity.
Different hypotheses may be formulated with respect to the role(s)
played by DCIR once expressed on the surface of CD4
+ T cells.
It can be hypothesized that induction of apoptosis increases
virus attachment/entry likely through DCIR expression on the
surface of CD4
+ T cells (Figure 10). This theory is supported by
our results showing that the H2O2-mediated induction of apoptosis
in CD4
+ T cells and DCIR expression are not accompanied by a
modulation of surface expression of two other attachment factors
for HIV-1, i.e. DC-SIGN and CD4. DCIR carries an immunor-
eceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic
tail that is thought to be responsible for the immunoregulatory role
played by this cell surface molecule. The intracellular ITIM motif
of DCIR is involved in SHP-1 recruitment [52], a tyrosine
phosphatase known for its important role in maintaining cellular
homeostasis [53]. The protein tyrosine phosphatase SHP-1 has
also been shown to regulate HIV-1 transcription [54] and inhibit
antigen-receptor-induced apoptosis [55]. Interestingly, DCIR-
expressing cells following acute HIV-1 infection display a cell
cycle arrest (data not shown), which might permit virus attachment
despite the appearance of a pre-apoptotic state. Studies are
currently performed to address this possibility. Thus, the life cycle
of HIV-1 can be affected in several ways by the newly expressed
DCIR and recruited SHP-1 molecules.
It can also be postulated that DCIR expression may lead to
phagocytosis by macrophages and DCs of apoptotic CD4
+ T cells
also infected with HIV-1, thereby promoting viral propagation
and infection of such antigen-presenting cells. It is well established
that macrophages play a central role in the pathogenesis of HIV-1
infection, functioning as stable viral reservoir due to their ability to
resist HIV-1-mediated cytopathicity. Of importance to note is the
previous report showing that phagocytosis of apoptotic cells
induced an increase in HIV-1 replication in macrophages [56].
Similarly, we observed that HIV-1 replication in macrophages is
enhanced when such cells are co-cultured with DCIR-positive
apoptotic CD4
+ T cells treated with H2O2 (data not shown).
Additionally, instead of inducing an inflammatory immune
response, phagocytosis of DCIR-expressing apoptotic cells might
promote the generation of suppressor macrophages as described
previously for bacterial infections [57] and tumor cells [58]. This
would allow microorganisms such as HIV-1 to escape the immune
system. Alternatively, it is possible that DCIR is induced after
HIV-1 infection because it acts as a death signal for the cell and/or
as a sign to promote phagocytosis. It can also be proposed that
DCIR facilitates HIV-1 attachment before cell death, a process
leading to more extensive virus dissemination across the organism.
Supplementary experiments are warranted to validate these non-
mutually exclusive hypotheses.
Together, our work represents the first evidence that DCIR can
serve as a marker for apoptosis in the context of an HIV-1
infection. Additional studies are needed to define more firmly
whether there is a connection between the chronic inflammatory
state seen in HIV-1-infected persons and DCIR expression in
CD4
+ T cells. Importantly, the exact contribution of the
immunoreceptor DCIR to HIV-1 pathogenesis needs to be
delineated because it might provide novel therapeutic avenues.
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Reagents
Recombinant human interleukin-2 (rhIL-2) and the non-nucleo-
side reverse transcriptase inhibitor EFV were obtained from the
AIDS Repository Reagent Program (Germantown, MD). The
mitogenic agent phytohemagglutinin-L (PHA-L) was purchased from
Sigma (St-Louis, MO). The culture medium for human primary
CD4
+ T cellsconsisted of RPMI-1640 supplemented with 10% foetal
bovine serum (FBS), penicillin G (100 U/ml), streptomycin (100 U/
ml), glutamine (2 mM), which were all purchased from Wisent (St-
Bruno, QC), and primocine, obtained from Amaxa Biosystems
(Gaithersburg, MD).The culturemedium for 293T cellswas made of
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% FBS and penicillin G (100 U/ml), streptomycin (100 U/ml),
and glutamine (2 mM) (Invitrogen, Burlington, Canada).
Antibodies
R-Phycoerythrin (R-PE)-conjugated and fluorescein isothiocya-
nate (FITC)-labelled anti-DCIR monoclonal antibodies (clone
216110) and the corresponding isotype-matched irrelevant control
antibody (Ab) were purchased from R&D Systems (Minneapolis,
MN). The FITC-labelled anti-DC-SIGN monoclonal antibody (Ab)
(clone eB-h209) and the appropriate control Ab were purchased
from eBioscience (San Diego, CA). R-PE-labelled anti-HSA Ab
(clone M1/69) was purchased from Invitrogen (Burlington, USA),
whereasbiotin-taggedanti-HSA(cloneM1/69)waspurchasedfrom
BD Biosciences (Mississauga, ON). PE-Cy5 anti-streptavidin Ab
was obtained from eBioscience and the FITC-conjugated anti-p24
from Beckman Coulter (Mississauga, ON).
Production of viral stocks
Virions were produced upon transient transfection of human
embryonic kidney 293T cells as previously described [59]. The
infectious molecular clones used in this study included pNL4-3/
Balenv (R5-tropic), pNL4-3 (X4-tropic) and its derivative pNL4-3-
IRES-HSA (X4-tropic). The pNL4-3-IRES-HSA molecular con-
struct was obtained by replacing the enhanced green fluorescent
protein (eGFP) gene in the NLENG1-IRES vector (kindly supplied
by D.N. Levy, New York University College of Dentistry, New
York, NY) [60] with the coding sequence for mouse heat stable
antigen (HSA) [29]. Experiments were also carried out with NL4-
3-based mutant deleted in Nef (kindly supplied by S. Venkatesan,
National Institute of Allergy and Infectious Diseases, Bethesda,
MD) or Vpr (kindly provided by E.A. Cohen, Institut de
Recherches Cliniques de Montre ´al, Montre ´al, QC). The virus-
containing supernatants were filtered through a 0.22 mm cellulose
acetate syringe filter, ultracentrifugated and normalized for virion
content using an in-house sensitive double-antibody sandwich
enzyme-linked immunosorbent assay (ELISA) specific for the viral
p24 protein [61].
Cell culture
Purified human primary CD4
+ T cells were isolated from
peripheral blood mononuclear cells (PBMCs) using a negative
selection kit according to the manufacturer’s instructions (Stem-
Cell Technologies, Vancouver, BC). Cells were obtained from
anonymous and paid, healthy volunteer donors that were
specifically solicited for provision of these samples. Healthy
subjects signed an informed consent approved by the Centre
Hospitalier de l’Universite ´ Laval Institutional Review Board.
These cells were either left untreated (to obtain quiescent cells) or
activated with PHA-L (1 mg/ml) for 3 days prior their use (to
obtain mitogen-stimulated cells) and maintained in complete
RPMI-1640 culture medium supplemented with rhIL-2 (30 U/ml)
at a density of 2610
6 cells/ml. Experiments were performed with
cell preparations containing a minimal amount of contaminants as
demonstrated previously (i.e. CD4
+ T cells: purity .98%) [62].
Figure 10. Proposed working models for DCIR involvement in HIV-1 infection. DCIR expression is promoted not only in cells productively
infected with HIV-1 but also in bystander cells via both a mitochondrial (intrinsic) caspase-dependent apoptotic pathway and a caspase-independent
apoptotic process relying on AIF. The resulting DCIR induction on the surface of CD4
+ T cells can affect virus replication by various means. For
example, virus binding can be increased through DCIR, a process leading to a more efficient HIV-1 propagation. Moreover, the cell cycle arrest seen in
DCIR-expressing cells can also promote virus attachment and the ensuing HIV-1 transmission despite apoptosis induction because of the association
between DCIR and SHP-1. It can also be postulated that DCIR expression on the surface of apoptotic CD4
+ T cells also infected with HIV-1 might
facilitate phagocytosis by macrophages and DCs, thereby favoring infection of such antigen-presenting cells and viral propagation.
doi:10.1371/journal.ppat.1001188.g010
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+ T cells from HIV-1 patients
Patient samples were obtained from two aviremic HIV-1-
infected patients that were undergoing antiretroviral therapy
(kindly provided by Dr. Rafick-Pierre Se ´kaly, Universite ´d e
Montre ´al, Montre ´al, QC) and also from three additional viremic
and treatment-naive patients (kindly supplied by Dr. Jean-Pierre
Routy at McGill University through the FRSQ - Re ´seau SIDA et
Maladies Infectieuses) [63]. Purification of CD4
+ T cells was
achieved using magnetic beads as described above. The first
aviremic donor had a CD4
+ T cell count of 463/mm
3 and was
undergoing a combined antiretroviral therapy consisting of 3TC,
EFV and abacavir. The second aviremic donor had a CD4
+ T cell
count of 499/mm
3 and was treated with D4T and atazanavir. In
both individuals, the viral load was undetectable (i.e. ,50 copies/
ml). The CD4
+ T cell counts for viremic/untreated patients A, B
and C were 290/mm
3, 520/mm
3 and 420/mm
3 respectively,
whereas their respective plasma viral loads were 224610
3,
172610
3 and 83610
3 HIV-1 RNA per ml.
Ethics statement
Cells were obtained from anonymous and paid, healthy
volunteer donors that were specifically solicited for provision of
these samples. Healthy subjects signed an informed consent
approved by the Centre Hospitalier de l’Universite ´ Laval
Institutional Review Board. Patient samples were obtained from
peripheral blood in accordance with the guidelines of the
Institutional Bioethics Committee. All subjects signed an ethics
board-approved informed consent form.
HIV-1 infection of CD4
+ T cells
In some experiments, purified CD4
+ T cells (1610
6) were
incubated for 2 h with NL4-3, Nef-deleted NL4-3, Vpr-deleted
NL4-3, or NL4-3/Balenv (100 ng of p24). After three extensive
washes with phosphate-buffered saline (PBS), the cells were
cultured for 3 days in complete RPMI-1640 culture medium
supplemented with rhIL-2 (30 U/ml), before staining and flow
cytometry analysis. For other infection studies, CD4
+ T cells were
incubated for 2 or 3 days with NL4-3-IRES-HSA (100 ng p24/10
6
cells), in the absence or presence of EFV (50 nM). Mock-infected
cells were used as negative controls.
Studies with cell-free supernatants
Purified CD4
+ T cells (1610
6) were initially infected for 3 days
with NL4-3. Next, supernatants from cells acutely infected with
HIV-1 were filtrated and ultracentrifugated to eliminate cellular
debris. Finally, cells were incubated with such cell-free superna-
tants and DCIR expression and apoptosis were monitored by flow
cytometry. Controls consisted of cells incubated with cell-free
supernatants from mock-infected cells.
Flow cytometric analyses
Purified cells (1610
6) were incubated for 45 min at 4uC with
a combination of antibodies made of either FITC-anti-DCIR
(0.25 mg) and R-PE-anti-HSA (1 mg), R-PE-anti-DCIR (0.25 mg)
and FITC-VAD-FMK (0.5 mg), or R-PE-anti-HSA (1 mg) and
FITC-VAD-FMK (0.5 mg). Non-specific staining was assessed by
usinganisotype-matched irrelevantcontrolAbforDCIR (i.e.FITC-
or R-PE-labeled IgG1) or mock-infected cells for HSA. Cells were
then washed twice with PBS and 0.5% bovine serum albumin. Cells
were fixed in 2% paraformaldehyde for 30 min at 4uC. Cell surface
expression of DCIR and HSA was monitored using an Epics ELITE
ESP apparatus (Coulter Electronics, Burlington, ON). Single stained
cells were used as controls for compensation adjustments.
Catalase assay
Purified CD4
+ T cells (1610
6) were first pretreated with PEG-
catalase (200 U/ml) (Sigma) for 10 min at 37uC. Next, cells were
infected with NL4-3-IRES-HSA virions (100 ng of p24) and PEG-
catalase was added to the culture medium every day. Flow
cytometry analyses were performed to assess the percentage of cells
positive for DCIR and FITC-VAD-FMK.
Apoptosis studies
Apoptosis was induced by incubating resting or PHA-activated
CD4
+ T cells (1610
6 cells/ml) with different concentrations of
H2O2 for increasing time lengths. Where indicated, apoptosis was
induced by a treatment for 16 h at 37uC with the protein kinase C
inhibitor staurosporine (1 mg/ml). The cell-permeable, FITC-
conjugated, pan-caspase inhibitor FITC-VAD-FMK (R&D Sys-
tems) was used to detect activated caspases in CD4
+ T cells by flow
cytometry. Briefly, in a 24-well culture plate, cells (1610
6)i na
final volume of 1 ml were stained directly with 10 ml of FITC-
VAD-FMK and left at 37uC in the dark during the last 30 min of
the apoptosis induction period. Cells were washed once in PBS to
remove unbound reagent and fixed with paraformaldehyde or
labeled with another Ab before flow cytometry analysis. Inhibition
of apoptosis was achieved by pre-treating cells with Z-VAD-FMK
(50 mM) (R&D Systems) for 1 h before H2O2 stimulation or HIV-
1 pulsing. It is known that Z-VAD-FMK is an irreversible caspase
inhibitor that binds to the active site of activated proteases and
displays low cytotoxicity. Experiments aimed at studying the
contribution of caspase-independent apoptotic pathway were
performed using NAC (5 mM) from Sigma because this
compound prevents nuclear translocation of AIF [64].
HIV-1 binding/entry, infection and transfer experiments
Purified CD4
+ T cells were treated with H2O2 (30 mM) during
16 h before performing the following experimental procedures. For
the binding/entry assay, cells (1610
6) were incubated for 60 min at
37uC with NL4-3 (100 ng of p24). After three extensive washes with
PBS to remove unabsorbed viruses, HIV-1 binding/entry was
quantified by estimating the p24 content. For the infection assay,
CD4
+Tc e l l s( 1 610
6)wereincubatedwithNL4-3(100 ng ofp24)for
2 h.After three extensivewashes with PBS, the cells were cultured in
complete RPMI-1640 culture medium supplemented with rhIL-2
(30 U/ml). Virus production was estimated by assessing the p24
levels in cell-free culture supernatants. For the transfer study, CD4
+
Tc e l l s( 1 610
6) were incubated with NL4-3 (100 ng of p24) for 2 h
and after washes, autologous activated CD4
+ Tc e l l s( 1 610
6)w e r e
added (ratio 1:1) in complete RPMI-1640 culture medium
supplemented with rhIL-2 (30 U/ml). Every two days, half of the
medium was removed and kept frozen at 220uC and fresh medium
was added to the culture. Virus production was estimated by
measuring the p24 levels in cell-free culture supernatants. Virus
transmission was also assessed using purified DCIR-negative and -
positive cells. In brief, CD4
+ T cells were first exposed to H2O2 to
induce DCIR expression. Next, DCIR-negative and DCIR-positive
cellswereisolatedandused separatelyinHIV-1transferexperiments
as described above. Cell isolation was achieved using the EasySep
Biotin Selection kit according to the manufacturer’s instructions with
slight modifications (StemCell Technologies Inc., Vancouver, BC).
The biotinylated anti-DCIR antibody (clone 216110 from R&D
Systems) was used at a final concentration of 3 mg/ml. In some
experiments, a dual staining technique was used to estimate the
percentage of cells expressing surface DCIR and intracellular p24 by
flow cytometry. Staining of the intracellular viral p24 core protein
was achieved using the BD Cytofix/Cytoperm kit (BD Biosciences)
and the monoclonal KC57 anti-p24 Ab (Beckman Coulter).
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Statistical analyses were carried out according to the methods
outlined in Zar [65] and Sokal and Rohlf [66]. Means were
compared using Student’s t test. P values of less than 0.05 were
deemed statistically significant. Calculations were performed with
the GraphPad Prism software.
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